Global Lymphedema Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

Global lymphedema treatment market is expected to reach USD 1,866, 576.80thousand by 2030 from USD 902,392.61 thousand in 2022 growing at the CAGR of 9.8% in the forecast period of 2023 to 2030.The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Global Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable, and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and rest of Asia-Pacific, Brazil, Argentina , Peru, and rest of South America, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Lymphedema Treatment Market Dynamics

Driver
Rising number of lymphedema cases around the globe
Restrain
High costs of treatment
Opportunity
Partnership and agreement by market players

Market Players

Some of the key market players operating in the global lymphedema treatment market are listed below:

medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Sanyleg Srl a socio unico
AIROS Medical, Inc.
Tactile Medical
BIOCOMPRESSION SYSTEMS
Lohmann & Rauscher GmbH & Co. KG
Mego Afek ltd.
ThermoTek
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
HERANTIS PHARMA Plc
Huntleigh Healthcare Limited
Avet Pharmaceuticals Inc
KOYA MEDICAL

1 INTRODUCTION 41

1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43

2 MARKET SEGMENTATION 46

2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 PRODUCT TYPE LIFELINE CURVE 52
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.9 DBMR MARKET POSITION GRID 54
2.10 MARKET END USER COVERAGE GRID 55
2.11 VENDOR SHARE ANALYSIS 56
2.12 SECONDARY SOURCES 57
2.13 ASSUMPTIONS 57

3 EXECUTIVE SUMMARY 58

4 PREMIUM INSIGHTS 62

4.1 PESTEL'S ANALYSIS 63
4.2 PORTER'S MODEL 64

5 PIPELINE ANALYSIS FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 65

6 EPIDEMIOLOGY 66

7 REGULATORY GUIDELINES FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 67

7.1 U.S. 67
7.2 EUROPE 68
7.3 INDIA 68
7.4 MEXICO 69
7.5 CANADA 69

8 MARKET OVERVIEW 71

8.1 DRIVERS 73
- 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY 73
- 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 73
- 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 74
- 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 74
8.2 RESTRAINTS 75
- 8.2.1 HIGH COST OF TREATMENT 75
- 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 76
8.3 OPPORTUNITIES 76
- 8.3.1 INCREASING DRUG APPROVALS 76
- 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 77
8.4 CHALLENGES 77
- 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 77
- 8.4.2 LIMITED REIMBURSEMENT SCENARIO 77

9 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 79

9.1 OVERVIEW 80
9.2 COMPRESSION THERAPY 81
- 9.2.1 COMPRESSION PUMPS 82
- 9.2.2 COMPRESSION GARMENTS 82
  - 9.2.2.1 COMPRESSION STOCKINGS 82
  - 9.2.2.2 COMPRESSION SLEEVES 82
  - 9.2.2.3 OTHERS 83
- 9.2.3 COMPRESSION BANDAGES & WRAPS 83
- 9.2.4 OTHERS 83
  - 9.2.4.1 STATIC COMPRESSION THERAPY 83
  - 9.2.4.2 DYNAMIC COMPRESSION THERAPY 83
9.3 SURGERY 84
- 9.3.1 LYMPHOVENOUS TRANSPLANT 84
- 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 84
- 9.3.3 LIPOSUCTION 85
- 9.3.4 OTHERS 85
9.4 DRUG THERAPY 85
- 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 86
- 9.4.2 RETINOIDS 86
- 9.4.3 ANTIBIOTICS 86
- 9.4.4 OTHERS 86
9.5 LASER THERAPY 87
9.6 OTHERS 88

10 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE 89

10.1 OVERVIEW 90
10.2 SECONDARY LYMPHEDEMA 91
10.3 PRIMARY LYMPHEDEMA 92
- 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 92
- 10.3.2 CONGENITAL LYMPHEDEMA 93
- 10.3.3 LYMPHEDEMA TARDA 93

11 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 94

11.1 OVERVIEW 95
11.2 LOWER EXTREMITY 96
11.3 UPPER EXTREMITY 97
11.4 GENITALIA 98

12 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 99

12.1 OVERVIEW 100
12.2 ADULT 101
12.3 GERIATRIC 102
12.4 PEDIATRIC 102

13 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 103

13.1 OVERVIEW 104
13.2 ORAL 105
13.3 INJECTABLE 106
13.4 TOPICAL 107

14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER 108

14.1 OVERVIEW 109
14.2 HOSPITAL 110
14.3 SPECIALTY CLINICS 111
14.4 AMBULATORY SURGICAL CENTERS 112
14.5 OTHERS 113

15 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 114

15.1 OVERVIEW 115
15.2 PHARMACY STORES 116
15.3 DIRECT TENDER 117
15.4 OTHERS 118

16 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION 119

16.1 OVERVIEW 120
16.2 NORTH AMERICA 124
- 16.2.1 U.S. 128
- 16.2.2 CANADA 131
- 16.2.3 MEXICO 135
16.3 EUROPE 138
- 16.3.1 GERMANY 142
- 16.3.2 FRANCE 146
- 16.3.3 U.K. 150
- 16.3.4 ITALY 154
- 16.3.5 RUSSIA 157
- 16.3.6 SPAIN 161
- 16.3.7 TURKEY 165
- 16.3.8 NETHERLANDS 169
- 16.3.9 SWITZERLAND 173
- 16.3.10 BELGIUM 177
- 16.3.11 POLAND 181
- 16.3.12 AUSTRIA 185
- 16.3.13 HUNGARY 189
- 16.3.14 NORWAY 193
- 16.3.15 IRELAND 197
- 16.3.16 LITHUANIA 201
- 16.3.17 REST OF EUROPE 205
16.4 ASIA-PACIFIC 206
- 16.4.1 CHINA 210
- 16.4.2 JAPAN 214
- 16.4.3 INDIA 218
- 16.4.4 SOUTH KOREA 221
- 16.4.5 AUSTRALIA 225
- 16.4.6 INDONESIA 229
- 16.4.7 SINGAPORE 233
- 16.4.8 PHILIPPINES 237
- 16.4.9 THAILAND 241
- 16.4.10 MALAYSIA 245
- 16.4.11 VIETNAM 249
- 16.4.12 REST OF ASIA-PACIFIC 253
16.5 SOUTH AMERICA 254
- 16.5.1 BRAZIL 259
- 16.5.2 ARGENTINA 264
- 16.5.3 PERU 269
- 16.5.4 REST OF SOUTH AMERICA 274
16.6 MIDDLE EAST AND AFRICA 275
- 16.6.1 SOUTH AFRICA 279
- 16.6.2 SAUDI ARABIA 283
- 16.6.3 EGYPT 287
- 16.6.4 U.A.E. 291
- 16.6.5 ISRAEL 294
- 16.6.6 KUWAIT 298
- 16.6.7 REST OF MIDDLE EAST AND AFRICA 302

17 GLOBAL LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 303

17.1 COMPANY SHARE ANALYSIS: GLOBAL 303
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304
17.3 COMPANY SHARE ANALYSIS: EUROPE 305
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306

18 COMPANY PROFILE 307

18.1 TACTILE MEDICAL 307
- 18.1.1 COMPANY SNAPSHOT 307
- 18.1.2 REVENUE ANALYSIS 307
- 18.1.3 COMPANY SHARE ANALYSIS 308
- 18.1.4 PRODUCT PORTFOLIO 308
- 18.1.5 RECENT DEVELOPMENT 308
18.2 ESSITY (BSN MEDICAL GMBH) 309
- 18.2.1 COMPANY SNAPSHOT 309
- 18.2.2 COMPANY SHARE ANALYSIS 309
- 18.2.3 PRODUCT PORTFOLIO 310
- 18.2.4 RECENT DEVELOPMENT 310
18.3 3M 311
- 18.3.1 COMPANY SNAPSHOT 311
- 18.3.2 REVENUE ANALYSIS 311
- 18.3.3 COMPANY SHARE ANALYSIS 312
- 18.3.4 PRODUCT PORTFOLIO 312
- 18.3.5 RECENT DEVELOPMENTS 312

18.4 CARDINAL HEALTH 313
- 18.4.1 COMPANY SNAPSHOT 313
- 18.4.2 REVENUE ANALYSIS 313
- 18.4.3 COMPANY SHARE ANALYSIS 314
- 18.4.4 PRODUCT PORTFOLIO 314
- 18.4.5 RECENT DEVELOPMENT 314
18.5 LOHMANN & RAUSCHER GMBH & CO. KG 315
- 18.5.1 COMPANY SNAPSHOT 315
- 18.5.2 COMPANY SHARE ANALYSIS 315
- 18.5.3 PRODUCT PORTFOLIO 316
- 18.5.4 RECENT DEVELOPMENT 316
18.6 AIROS MEDICAL, INC. 317
- 18.6.1 COMPANY SNAPSHOT 317
- 18.6.2 PRODUCT PORTFOLIO 317
- 18.6.3 RECENT DEVELOPMENT 317
18.7 AVET PHARMACEUTICALS INC. 318
- 18.7.1 COMPANY SNAPSHOT 318
- 18.7.2 PRODUCT PORTFOLIO 318
- 18.7.3 RECENT DEVELOPMENT 318
18.8 BIOCOMPRESSION SYSTEMS 319
- 18.8.1 COMPANY SNAPSHOT 319
- 18.8.2 PRODUCT PORTFOLIO 319
- 18.8.3 RECENT DEVELOPMENT 319
18.9 CONVATEC INC. 321
- 18.9.1 COMPANY SNAPSHOT 321
- 18.9.2 PRODUCT PORTFOLIO 321
- 18.9.3 RECENT DEVELOPMENT 321
18.10 HERANTIS PHARMA PLC 322
- 18.10.1 COMPANY SNAPSHOT 322
- 18.10.2 RECENT DEVELOPMENT 322
18.11 HUNTLEIGH HEALTHCARE LIMITED 323
- 18.11.1 COMPANY SNAPSHOT 323
- 18.11.2 PRODUCT PORTFOLIO 323
- 18.11.3 RECENT DEVELOPMENT 323
18.12 JUZO 324
- 18.12.1 COMPANY SNAPSHOT 324
- 18.12.2 PRODUCT PORTFOLIO 324
- 18.12.3 RECENT DEVELOPMENT 324
18.13 KOYA MEDICAL 325
- 18.13.1 COMPANY SNAPSHOT 325
- 18.13.2 PRODUCT PORTFOLIO 325
- 18.13.3 RECENT DEVELOPMENT 325
18.14 MEDI GMBH & CO. KG 326
- 18.14.1 COMPANY SNAPSHOT 326
- 18.14.2 PRODUCT PORTFOLIO 326
- 18.14.3 RECENT DEVELOPMENT 326
18.15 MEGO AFEK LTD 327
- 18.15.1 COMPANY SNAPSHOT 327
- 18.15.2 PRODUCT PORTFOLIO 327
- 18.15.3 RECENT DEVELOPMENT 327
18.16 PAUL HARTMANN AG 329
- 18.16.1 COMPANY SNAPSHOT 329
- 18.16.2 REVENUE ANALYSIS 329
- 18.16.3 PRODUCT PORTFOLIO 330
- 18.16.4 RECENT DEVELOPMENTS 330
18.17 SANYLEG SRL A SOCIO UNICO 331
- 18.17.1 COMPANY SNAPSHOT 331
- 18.17.2 PRODUCT PORTFOLIO 331
- 18.17.3 RECENT DEVELOPMENT 331
18.18 SIGVARIS GROUP 332
- 18.18.1 COMPANY SNAPSHOT 332
- 18.18.2 PRODUCT PORTFOLIO 332
- 18.18.3 RECENT DEVELOPMENTS 333
18.19 SMITH +NEPHEW 334
- 18.19.1 COMPANY SNAPSHOT 334
- 18.19.2 REVENUE ANALYSIS 334
- 18.19.3 PRODUCT PORTFOLIO 335
- 18.19.4 RECENT DEVELOPMENT 335
18.20 THERMOTEK 336
- 18.20.1 COMPANY SNAPSHOT 336
- 18.20.2 PRODUCT PORTFOLIO 336
- 18.20.3 RECENT DEVELOPMENT 336

19 QUESTIONNAIRE 337

20 RELATED REPORTS 341

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 65
TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 74
TABLE 3 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 81
TABLE 4 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 81
TABLE 5 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 82
TABLE 6 GLOBAL COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 82
TABLE 7 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 83
TABLE 8 GLOBAL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 9 GLOBAL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 84
TABLE 10 GLOBAL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 11 GLOBAL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
TABLE 12 GLOBAL LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 13 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 91
TABLE 15 GLOBAL SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
TABLE 16 GLOBAL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 17 GLOBAL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 92
TABLE 18 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 96
TABLE 19 GLOBAL LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
TABLE 20 GLOBAL UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
TABLE 21 GLOBAL GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
TABLE 22 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 101
TABLE 23 GLOBAL ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
TABLE 24 GLOBAL GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
TABLE 25 GLOBAL PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
TABLE 26 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
TABLE 27 GLOBAL ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
TABLE 28 GLOBAL INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 29 GLOBAL TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 30 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
TABLE 31 GLOBAL HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
TABLE 32 GLOBAL SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
TABLE 33 GLOBAL AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
TABLE 34 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 113
TABLE 35 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 116
TABLE 36 GLOBAL PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 116
TABLE 37 GLOBAL DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
TABLE 38 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 118
TABLE 39 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
TABLE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 124
TABLE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 42 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 124
TABLE 43 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 125
TABLE 44 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 125
TABLE 45 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 46 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 48 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 49 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 126
TABLE 50 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 126
TABLE 51 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 52 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 53 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 54 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 55 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 128
TABLE 56 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 128
TABLE 57 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 128
TABLE 58 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 59 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 60 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 61 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 62 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 130
TABLE 63 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 130
TABLE 64 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 130
TABLE 65 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 130
TABLE 66 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
TABLE 67 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 68 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 131
TABLE 69 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 131
TABLE 70 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 132
TABLE 71 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 72 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 73 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 74 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 75 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 133
TABLE 76 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 133
TABLE 77 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 133
TABLE 78 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
TABLE 79 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 134
TABLE 80 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 81 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 135
TABLE 82 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 135
TABLE 83 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 135
TABLE 84 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 85 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 86 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 87 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 88 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 137
TABLE 89 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 137
TABLE 90 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 137
TABLE 91 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 92 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 93 EUROPE LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 138
TABLE 94 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 95 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 139
TABLE 96 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 139
TABLE 97 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 139
TABLE 98 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 99 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 100 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 101 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 102 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 140
TABLE 103 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 141
TABLE 104 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
TABLE 105 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
TABLE 106 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 107 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 108 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
TABLE 109 GERMANY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
TABLE 110 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 142
TABLE 111 GERMANY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 112 GERMANY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 113 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 114 GERMANY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 115 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 144
TABLE 116 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 144
TABLE 117 GERMANY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
TABLE 118 GERMANY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
TABLE 119 GERMANY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 120 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 121 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 146
TABLE 122 FRANCE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 146
TABLE 123 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 146
TABLE 124 FRANCE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 125 FRANCE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 126 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 127 FRANCE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 128 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 148
TABLE 129 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 148
TABLE 130 FRANCE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 148
TABLE 131 FRANCE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 148
TABLE 132 FRANCE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 149
TABLE 133 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 134 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 150
TABLE 135 UNITED KINGDOM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 150
TABLE 136 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 150
TABLE 137 UNITED KINGDOM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 138 UNITED KINGDOM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 139 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 140 UNITED KINGDOM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 141 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 152
TABLE 142 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 152
TABLE 143 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
TABLE 144 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 152
TABLE 145 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
TABLE 146 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 147 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 154
TABLE 148 ITALY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 154
TABLE 149 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 154
TABLE 150 ITALY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 151 ITALY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 152 ITALY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 153 ITALY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 154 ITALY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 156
TABLE 155 ITALY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 156
TABLE 156 ITALY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
TABLE 157 ITALY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 156
TABLE 158 ITALY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 156
TABLE 159 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 160 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
TABLE 161 RUSSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
TABLE 162 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 157
TABLE 163 RUSSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 164 RUSSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 165 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 166 RUSSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 167 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 159
TABLE 168 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 159
TABLE 169 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 159
TABLE 170 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 159
TABLE 171 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 160
TABLE 172 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 173 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
TABLE 174 SPAIN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
TABLE 175 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 161
TABLE 176 SPAIN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 177 SPAIN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 178 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 179 SPAIN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 180 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 163
TABLE 181 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 163
TABLE 182 SPAIN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 163
TABLE 183 SPAIN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 163
TABLE 184 SPAIN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 164
TABLE 185 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 186 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
TABLE 187 TURKEY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
TABLE 188 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 165

LIST OF FIGURES

FIGURE 1 GLOBAL LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 46
FIGURE 2 GLOBAL LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 49
FIGURE 3 GLOBAL LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 50
FIGURE 4 GLOBAL LYMPHEDEMA TREATMENT MARKET: GLOBAL VS REGIONAL ANALYSIS 51
FIGURE 5 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 51
FIGURE 6 GLOBAL LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 53
FIGURE 7 GLOBAL LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 54
FIGURE 8 GLOBAL LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 55
FIGURE 9 GLOBAL LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 56
FIGURE 10 GLOBAL LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 61
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 62
FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 62
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL LYMPHEDEMA TREATMENT MARKET 72
FIGURE 14 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 80
FIGURE 15 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 90
FIGURE 16 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 95
FIGURE 17 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 100
FIGURE 18 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 104
FIGURE 19 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 109
FIGURE 20 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 115
FIGURE 21 GLOBAL LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2022) 121
FIGURE 22 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 303
FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 304
FIGURE 24 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 305
FIGURE 25 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 306